UroGen Pharma Ltd. Increase (Decrease) in Restricted Cash
UroGen Pharma Ltd. (URGN) reported Increase (Decrease) in Restricted Cash of $4.00 thousand for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-12.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRestrictedCash · last filed 2019-11-12
- UroGen Pharma Ltd. increase (decrease) in restricted cash for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
- UroGen Pharma Ltd. increase (decrease) in restricted cash for the quarter ending 2018-12-31 was $2.00K.
- UroGen Pharma Ltd. increase (decrease) in restricted cash for the quarter ending 2018-09-30 was $1.00K, a 99.00% decline year-over-year.
- UroGen Pharma Ltd. increase (decrease) in restricted cash for the quarter ending 2017-12-31 was -$100.00K.
- UroGen Pharma Ltd. increase (decrease) in restricted cash for fiscal 2018 was $54.00K, a 980.00% increase from fiscal 2017.
- UroGen Pharma Ltd. increase (decrease) in restricted cash for fiscal 2017 was $5.00K, a 79.17% decline from fiscal 2016.
- UroGen Pharma Ltd. increase (decrease) in restricted cash for fiscal 2016 was $24.00K.
| Period end | Increase (Decrease) in Restricted Cash 3 month | Increase (Decrease) in Restricted Cash 6 month | Increase (Decrease) in Restricted Cash 9 month | Increase (Decrease) in Restricted Cash 12 month | Increase (Decrease) in Restricted Cash 12 month as first filed |
|---|---|---|---|---|---|
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $4.00K 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | $4.00K 10-Q · filed 2019-08-09 | ||||
| 2018-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $3.00K derived: sum of 2 quarters · filed 2019-11-12 | $54.00K 10-K · filed 2019-02-28 | ||
| 2018-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $52.00K 10-Q · filed 2019-11-12 | |||
| 2018-06-30 | $51.00K 10-Q · filed 2019-08-09 | ||||
| 2017-12-31 | -$100.00K derived: 10-K 12 month − 6-K 9 month · filed 2019-02-28 | $0.00 derived: sum of 2 quarters · filed 2019-02-28 | $1.00K derived: sum of 3 quarters · filed 2019-02-28 | $5.00K 10-K · filed 2019-02-28 | $105.00K 20-F · filed 2018-03-15 |
| 2017-09-30 | $100.00K derived: 6-K 9 month − 6-K 6 month · filed 2018-11-13 | $101.00K derived: sum of 2 quarters · filed 2018-11-13 | $105.00K 6-K · filed 2018-11-13 | ||
| 2017-06-30 | $1.00K derived: 6-K 6 month − 6-K 3 month · filed 2018-08-14 | $5.00K 6-K · filed 2018-08-14 | |||
| 2017-03-31 | $4.00K 6-K · filed 2018-05-15 | ||||
| 2016-12-31 | $24.00K 10-K · filed 2019-02-28 | $98.00K 20-F · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |